Cargando…

1002. Utilization of Alternative Β-lactams in Patients with Penicillin Hypersensitivity

BACKGROUND: The increased utilization of alternative agents due to recorded β-lactam allergies, such as aztreonam, fluoroquinolones, and vancomycin is leading to potentially worse clinical outcomes as well as an increase in multi-drug-resistant-organisms. We aim to determine whether β-lactam allergy...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamadeh, Leena, Patel, Sreya, Ajmal, Saira R, Levato, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811163/
http://dx.doi.org/10.1093/ofid/ofz360.866
_version_ 1783462413980401664
author Hamadeh, Leena
Patel, Sreya
Ajmal, Saira R
Levato, Joseph
author_facet Hamadeh, Leena
Patel, Sreya
Ajmal, Saira R
Levato, Joseph
author_sort Hamadeh, Leena
collection PubMed
description BACKGROUND: The increased utilization of alternative agents due to recorded β-lactam allergies, such as aztreonam, fluoroquinolones, and vancomycin is leading to potentially worse clinical outcomes as well as an increase in multi-drug-resistant-organisms. We aim to determine whether β-lactam allergy evaluation conducted by a pharmacist reduces the utilization of aztreonam in patients reporting a penicillin allergy. METHODS: This single-center, retrospective study was conducted at Advocate Christ Medical Center in patients ≥18 years of age with a documented penicillin allergy initiated on aztreonam upon admission from September 1, 2017 to August 31, 2018. A pharmacist driven β-lactam allergy history evaluation protocol was initiated on March 1, 2018 to identify patients who qualified for an alternative β-lactam, rather than aztreonam. Once identified, recommendations regarding these patients was discussed with the physician. The pre-intervention group was compared with patients initiated on aztreonam post-implementation of the pharmacist driven intervention. RESULTS: A total of 121 patients were included; 70 in the pre-intervention group, 51 in the post-intervention group. Post-intervention, significantly more patients had appropriate β-lactam allergy history documentation in the electronic medical record (38.6% vs. 60.8%; P = 0.02). After implementation of the pharmacist driven protocol, days on aztreonam per 1000 patient-days was significantly lower in the post-intervention group (4 [3–6] vs. 3 [2–6] P = 0.04). Within the post-intervention group, 34 pharmacist interventions were attempted, with 83% of those interventions being accepted. Of these patients, 50% had antibiotics discontinued, 43% were switched to a third or fourth-generation cephalosporin, and 7% were switched to a carbapenem. None of these patients experienced hypersensitivity when challenged with an alternative β-lactam. CONCLUSION: Implementation of a pharmacist-driven β-lactam allergy evaluation increased the appropriate use of β-lactams. Of the patients given an alternative β-lactam during their admission, none experienced a hypersensitivity reaction, which suggests their safe utilization in patients with reported penicillin hypersensitivity. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6811163
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68111632019-10-29 1002. Utilization of Alternative Β-lactams in Patients with Penicillin Hypersensitivity Hamadeh, Leena Patel, Sreya Ajmal, Saira R Levato, Joseph Open Forum Infect Dis Abstracts BACKGROUND: The increased utilization of alternative agents due to recorded β-lactam allergies, such as aztreonam, fluoroquinolones, and vancomycin is leading to potentially worse clinical outcomes as well as an increase in multi-drug-resistant-organisms. We aim to determine whether β-lactam allergy evaluation conducted by a pharmacist reduces the utilization of aztreonam in patients reporting a penicillin allergy. METHODS: This single-center, retrospective study was conducted at Advocate Christ Medical Center in patients ≥18 years of age with a documented penicillin allergy initiated on aztreonam upon admission from September 1, 2017 to August 31, 2018. A pharmacist driven β-lactam allergy history evaluation protocol was initiated on March 1, 2018 to identify patients who qualified for an alternative β-lactam, rather than aztreonam. Once identified, recommendations regarding these patients was discussed with the physician. The pre-intervention group was compared with patients initiated on aztreonam post-implementation of the pharmacist driven intervention. RESULTS: A total of 121 patients were included; 70 in the pre-intervention group, 51 in the post-intervention group. Post-intervention, significantly more patients had appropriate β-lactam allergy history documentation in the electronic medical record (38.6% vs. 60.8%; P = 0.02). After implementation of the pharmacist driven protocol, days on aztreonam per 1000 patient-days was significantly lower in the post-intervention group (4 [3–6] vs. 3 [2–6] P = 0.04). Within the post-intervention group, 34 pharmacist interventions were attempted, with 83% of those interventions being accepted. Of these patients, 50% had antibiotics discontinued, 43% were switched to a third or fourth-generation cephalosporin, and 7% were switched to a carbapenem. None of these patients experienced hypersensitivity when challenged with an alternative β-lactam. CONCLUSION: Implementation of a pharmacist-driven β-lactam allergy evaluation increased the appropriate use of β-lactams. Of the patients given an alternative β-lactam during their admission, none experienced a hypersensitivity reaction, which suggests their safe utilization in patients with reported penicillin hypersensitivity. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6811163/ http://dx.doi.org/10.1093/ofid/ofz360.866 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Hamadeh, Leena
Patel, Sreya
Ajmal, Saira R
Levato, Joseph
1002. Utilization of Alternative Β-lactams in Patients with Penicillin Hypersensitivity
title 1002. Utilization of Alternative Β-lactams in Patients with Penicillin Hypersensitivity
title_full 1002. Utilization of Alternative Β-lactams in Patients with Penicillin Hypersensitivity
title_fullStr 1002. Utilization of Alternative Β-lactams in Patients with Penicillin Hypersensitivity
title_full_unstemmed 1002. Utilization of Alternative Β-lactams in Patients with Penicillin Hypersensitivity
title_short 1002. Utilization of Alternative Β-lactams in Patients with Penicillin Hypersensitivity
title_sort 1002. utilization of alternative β-lactams in patients with penicillin hypersensitivity
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811163/
http://dx.doi.org/10.1093/ofid/ofz360.866
work_keys_str_mv AT hamadehleena 1002utilizationofalternativeblactamsinpatientswithpenicillinhypersensitivity
AT patelsreya 1002utilizationofalternativeblactamsinpatientswithpenicillinhypersensitivity
AT ajmalsairar 1002utilizationofalternativeblactamsinpatientswithpenicillinhypersensitivity
AT levatojoseph 1002utilizationofalternativeblactamsinpatientswithpenicillinhypersensitivity